Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 4:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 558 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Overweight or Obesity Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pediatric Quality of Life Among Population With Body Mass Index (BMI) Greater Than or Equal to 85%

NCT00714870
View directory record Official record
Conditions
Pediatric Obesity
Interventions
Behavioral nutrition and exercise program
Behavioral
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
10 Years to 20 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Sep 30, 2026, 4:31 AM EDT
Terminated Not applicable Interventional

Farming for Life - Health Impact of Organic Vegetable Prescriptions for Adults Living With or at Risk of Type 2 Diabetes

NCT03940300
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Food Supply, Poverty, Minority Health, Obesity
Interventions
Fresh organic vegetables
Dietary Supplement
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 30, 2026, 4:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolic Effects of Almond in the Longer-term Study

NCT01690936
View directory record Official record
Conditions
Obesity
Interventions
Almonds 43g/day
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Sep 30, 2026, 4:31 AM EDT
Completed Not applicable Interventional

A Mail and Video-based Weight Loss Trial in Breast Cancer Survivors

NCT02681965
View directory record Official record
Conditions
Breast Cancer Survivorship, Obesity
Interventions
LEAN book/videos
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Sep 30, 2026, 4:31 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women

NCT07224399
View directory record Official record
Conditions
Healhty, Overweight or Obesity
Interventions
BGM1812, Placebo
Drug
Lead sponsor
BrightGene Bio-Medical Technology Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Sep 30, 2026, 4:31 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

NCT06075667
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
10
States / cities
Decatur, Georgia • Meridian, Idaho • Topeka, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 30, 2026, 4:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Implementation of a Mediterranean Diet Program for Overweight or Obese Pregnant Women in a Low-resource Clinical Setting

NCT05868954
View directory record Official record
Conditions
Gestational Weight Gain, Diet, Healthy
Interventions
MedDiet Program, ACOG-based Dietary Program
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 30, 2026, 4:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Retrospective Chart Review of the 5 & 2 & 2 and 4 & 2 & 1 Plans

NCT02150837
View directory record Official record
Conditions
Obesity
Interventions
5 & 2 & 2 Plan, 4 & 2 & 1 Plan
Other
Lead sponsor
Medifast, Inc.
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Owings Mills, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Sep 30, 2026, 4:31 AM EDT
Recruiting Phase 1 Interventional

A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults

NCT07465965
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Semaglutide Nasal Spray, Placebo, Semaglutide Injection
Drug
Lead sponsor
Shanghai World Leader Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 30, 2026, 4:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Weight and/or Obesity on Sulfamethoxazole and Trimethoprim Concentrations

NCT01167452
View directory record Official record
Conditions
Obesity, Pharmacokinetics, MRSA, Tuberculosis, PCP
Interventions
Sulfamethoxazole/trimethoprim
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Sep 30, 2026, 4:31 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Study of How Exercise or Weight Loss Effects Metabolic Syndrome

NCT00292994
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Resistance, Obesity
Interventions
Exercise, Weight Loss
Behavioral
Lead sponsor
Yankton Clinical Research Alliance
Other
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Yankton, South Dakota
Source: ClinicalTrials.gov public record
Updated Feb 16, 2006 · Synced Sep 30, 2026, 4:31 AM EDT
Completed Phase 2 Interventional

A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

NCT00402077
View directory record Official record
Conditions
Overweight, Obesity
Interventions
pramlintide acetate, sibutramine, phentermine, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Sep 30, 2026, 4:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Weight and/or Obesity on Anidulafungin Drug Concentrations

NCT01307930
View directory record Official record
Conditions
Obesity, Mycoses
Interventions
Anidulafungin
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Sep 30, 2026, 4:31 AM EDT
Active, not recruiting Phase 2 Interventional

Aleniglipron Phase 2 Body Composition Study

NCT07169942
View directory record Official record
Conditions
Obesity, Overweight, or Chronic Weight Management
Interventions
aleniglipron or placebo
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
11
States / cities
Phoenix, Arizona • Chicago, Illinois • Richfield, Minnesota + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 30, 2026, 4:31 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer

NCT04931017
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Biopsy, Biospecimen Collection, Bronchoscopy, Extended Release Metformin Hydrochloride, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 30, 2026, 4:31 AM EDT
Completed Phase 3 Interventional Results available

A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity

NCT04102189
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Semaglutide, Placebo
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years to 17 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Los Angeles, California • Meridian, Idaho • Baton Rouge, Louisiana + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 30, 2026, 4:31 AM EDT
Completed Phase 2 Interventional

A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

NCT06683508
View directory record Official record
Conditions
Obesity, Overweight
Interventions
LY3549492, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
49
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 30, 2026, 4:31 AM EDT
Active, not recruiting Not applicable Interventional

4:3 Intermittent Fasting Intervention in Adults With Breast Cancer and Overweight or Obesity

NCT06399276
View directory record Official record
Conditions
Breast Cancer
Interventions
Weight Loss
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 30, 2026, 4:31 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

NCT07776509
View directory record Official record
Conditions
Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
Interventions
Lenbelintide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Escondido, California • Lincoln, California • Walnut Creek, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Sep 30, 2026, 4:31 AM EDT
Recruiting Phase 1 Interventional

Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

NCT07399678
View directory record Official record
Conditions
Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Interventions
ALV-100, Placebo
Drug
Lead sponsor
Alveus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Miami, Florida • Columbus, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Sep 30, 2026, 4:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Diet and/or Exercise-induced Weight Loss on Cardiovascular Risk Factors

NCT00588978
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
diet and/or exercise
Behavioral
Lead sponsor
Yale University
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Sep 30, 2026, 4:31 AM EDT
Completed Phase 2 Interventional

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

NCT05536804
View directory record Official record
Conditions
Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Northridge, California • Aurora, Colorado • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Sep 30, 2026, 4:31 AM EDT
Completed Not applicable Interventional

Hearty Meals for Mom- Pilot Study of Meal Delivery for Cardiometabolic Health During Pregnancy

NCT05512247
View directory record Official record
Conditions
Diet, Healthy, Pregnancy
Interventions
Meal Delivery
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 30, 2026, 4:31 AM EDT
Completed Phase 1 Interventional

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects

NCT06714955
View directory record Official record
Conditions
Non-diabetic Overweight or Obese
Interventions
Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week., Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week., Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.
Drug
Lead sponsor
BrightGene Bio-Medical Technology Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 30, 2026, 4:31 AM EDT